FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection By Ogkologos - February 7, 2025 790 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CHECKMATE-67T study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Impact of Multigene Germline Genetic Testing on Selection of Germline-Directed Therapy... August 27, 2021 Avapritinib Approved to Treat GIST with a Rare Gene Alteration February 6, 2020 Nirogacestat May Offer Hope to People with Desmoid Tumors May 1, 2023 Prognostic Role of ctDNA in Patients with Surgically Resectable Colorectal Cancer January 30, 2023 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Generic Enzalutamide FDA Approves Blinatumomab as Consolidation for CD19-positive Philadelphia Chromosome-negative B-Cell Precursor... FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single... Efficacy and Safety of Adjuvant Nivolumab for High-Risk Muscle-Invasive Urothelial Carcinoma...
